SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively trending due to renewed geopolitical focus on Greenland's strategic rare earth deposits, highlighted by U.S. administration comments and the appointment of a special envoy. The community is widely discussing the potential for government investment or partnership in CRML's Tanbreez project, viewing it as vital for Western supply chain independence and eagerly anticipating upcoming feasibility study results.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending with significant community enthusiasm, driven by landmark U.S. and U.K. defense contracts, notably an $816 million SDA award, which solidifies its strategic pivot to an end-to-end national security space partner. Investors are keenly focused on its successful Electron launches and the eagerly anticipated Neutron rocket debut, fueling conviction that RKLB is a generational investment in the rapidly expanding space industry.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid intense community speculation surrounding imminent government contract announcements, especially concerning its secure AI capabilities for defense and potential involvement in TSA modernization. This optimism is fueled by the company's recent strategic debt reduction and the completion of its Ask Sage acquisition, significantly strengthening its financial position and market offerings.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending amid an intense rally in memory and storage stocks, driven by soaring demand from AI infrastructure buildouts and rising prices for essential components. The community is actively debating if its rapid appreciation reflects a legitimate "memory supercycle" or an "overpriced bubble," with many expressing FOMO while others anticipate a pullback. This strong movement is widely seen as a reflection of the broader sector's response to unprecedented AI-driven data center needs.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing a surge in bullish sentiment, driven by significant trading volume and active options flow. The community is buzzing about strong technical signals, anticipating a major breakout past key resistance levels amidst a broader rotation into small-cap technology stocks and improving housing market outlook.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is experiencing a significant uplift following news of an $880 million data center deal in Israel and plans to be an early adopter of NVIDIA's Vera Rubin NVL72 platform. The community is actively discussing this as a major catalyst, fueling optimism for substantial price recovery and long-term growth within the burgeoning AI infrastructure sector, despite the stock's noted volatility.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending amidst sharp market volatility, primarily driven by recent downgrades from major financial institutions, which many in the community perceive as a manipulative tactic by competitors to acquire shares at a discount. This intense trading activity is prompting discussions of a strategic buying opportunity for long-term holders, anticipating strong upcoming earnings and potential S&P 500 inclusion, despite frustration over what's seen as repeated institutional tactics.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis is trending due to highly positive Phase 3 clinical trial results for its oral TYK2 inhibitor, envudeucitinib, in plaque psoriasis, which demonstrated strong skin clearance and a favorable safety profile. This breakthrough has prompted significant analyst price target increases and robust community discussion, with many anticipating the drug to be a best-in-class contender in a lucrative market. While some debate potential future offerings, the company's solid cash position and pipeline for other immune-mediated diseases like lupus are fueling bullish sentiment among traders.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is experiencing increased trading volume and positive gains, distinguishing itself amidst broader crypto market optimism and predictions for an altcoin season. The community is actively discussing its foundational utility in decentralized AI, DePIN, and secure data monetization via its Layer-2 network, supported by strong regulatory standing in Japan and ex-Sony leadership. This strategic positioning and technical breakouts are fueling bullish sentiment for significant growth, though some long-term investors remain cautious due to historical volatility.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending due to widespread reports of Eli Lilly nearing a multi-billion dollar acquisition, immediately sparking intense market speculation. This potential buyout highlights the strategic value of Ventyx's NLRP3 inhibitor pipeline, with the community actively discussing a possible bidding war among major pharmaceutical companies for its promising applications in chronic inflammatory, cardiometabolic, and neurodegenerative diseases. Many investors see Ventyx's assets as a crucial complementary class to the thriving GLP-1 market, also fueling strong short squeeze sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LEXX Hearing additional MTA partner speculation on my end.

$LLY stands out as the best potential additional MTA partner because DehydraTECH directly addresses Lilly’s biggest unmet need: making large, complex incretin peptides orally viable without unacceptable GI side effects. Unlike Novo, Lilly is not locked into SNAC or a proprietary oral delivery solution, giving it flexibility to evaluate an external platform. Tirzepatide and next-generation dual or triple agonists are larger and harder to absorb than semaglutide, increasing the value of a lipid-based delivery system that can improve absorption efficiency and smooth exposure. GI tolerability is a known limitation for incretins, and Lexaria’s human data already shows meaningful reductions in GI adverse events. Strategically, Lilly has shown willingness to partner externally when it accelerates timelines, and oral incretins remain a major growth opportunity.

Things could heat up fast with $NVO &amp; $LLY involved here 💰

Ricardo Joseph

Smitty

Traveller22

Turbofueled

Makingmillions192

Pete Finfrock

StockTwits for iOS

Lexaria Bioscience Corp

Lilly(Eli) & Co

Novo Nordisk A/S

 Hearing additional MTA partner speculation on my end.



 stands out as the best potential additional MTA partner because DehydraTECH directly addresses Lilly’s biggest unmet need: making large, complex incretin peptides orally viable without unacceptable GI side effects. Unlike Novo, Lilly is not locked into SNAC or a proprietary oral delivery solution, giving it flexibility to evaluate an external platform. Tirzepatide and next-generation dual or triple agonists are larger and harder to absorb than semaglutide, increasing the value of a lipid-based delivery system that can improve absorption efficiency and smooth exposure. GI tolerability is a known limitation for incretins, and Lexaria’s human data already shows meaningful reductions in GI adverse events. Strategically, Lilly has shown willingness to partner externally when it accelerates timelines, and oral incretins remain a major growth opportunity.

Things could heat up fast with 

@Makingmillions192 Fingers crossed for a bidding war!!